Patterns and predictors of first-line chemotherapy use among adults with advanced non-small cell lung cancer in the cancer research network

Lung Cancer

Volumn 78, Issue 3, 2012, Pages 245-252

  Ritzwoller, Debra P ^a   Carroll, Nikki M ^a   Delate, Thomas ^a   Hornbrook, Mark C ^b   Kushi, Lawrence ^c   Aiello Bowles, Erin J ^d   Freml, Jared M ^a   Huang, Karl ^c   Loggers, Elizabeth T ^d,e  

^a Kaiser Permanente Colorado   (United States)

^b CENTER FOR HEALTH RESEARCH   (United States)

^c DIVISION OF RESEARCH   (United States)

^d GROUP HEALTH RESEARCH INSTITUTE   (United States)

^e Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Advanced stage; Bevacizumab; Chemotherapy; Erlotinib; HMO; Non small cell lung cancer

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; ERLOTINIB; ETOPOSIDE; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER RESEARCH; CANCER STAGING; COHORT ANALYSIS; COMORBIDITY; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HEALTH CARE SURVEYS; HUMANS; INDUCTION CHEMOTHERAPY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; UNITED STATES;

EID: 84868302127     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2012.09.008     Document Type: Article

References (22)

1. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012, 62(1):10-29.
2. American Cancer Society. Lung cancer (non-small cell). Available at:; 2010 [accessed 20.03.12]. http://www.%20cancer.%20org/acs/groups/cid/documents/webcontent/003115-pdf.pdf.
3. Ramsey S.D., Howlader N., Etzioni R.D., Donato B. Chemotherapy use, outcomes, and costs for older persons with advanced non-small-cell lung cancer: evidence from surveillance, epidemiology and end results-Medicare. J Clin Oncol 2004, 22(24):4971-4978.
4. Fojo T., Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the 440 billion question. J Natl Cancer Inst 2009, 101(15):1044-1048.
5. Lang K., Marciniak M.D., Faries D., Stokes M., Buesching D., Earle C., et al. Trends and predictors of first-line chemotherapy use among elderly patients with advanced non-small cell lung cancer in the United States. Lung Cancer 2009, 63(2):264-270.
6. Li E.C., DeMartino J. Preliminary report: the development of the NCCN Comparative Therapeutic Index as a clinical evaluative process for existing data in oncology. J Natl Compr Cancer Netw 2010, 8(Suppl. 5):S1-S9.
7. Ritzwoller D.P., Carroll N., Delate T., O'Keeffe-Rossetti M., Fishman P.A., Loggers E.T., et al. Validation of electronic data on chemotherapy and hormone therapy use in HMOs. Med Care 2012, Apr 23.
8. Hornbrook M.C., Hart G., Ellis J.L., Bachman D.J., Ansell G., Greene S.M., et al. Building a virtual cancer research organization. J Natl Cancer Inst Monogr 2005, (35):12-25.
9. North American Association of Central Cancer Registries. NAACCR Strategic Management Plan. [accessed 26.08.11]. http://www.naaccr.org/Home.aspx.%202011.
10. Delate T., Bowles E.J., Pardee R., Wellman R.D., Habel L.A., Yood M.U., et al. Validity of eight integrated healthcare delivery organizations' administrative clinical data to capture breast cancer chemotherapy exposure. Cancer Epidemiol Biomarkers Prev 2012, 21(April (4)):637-680. [Epub 2012 Feb 15].
11. Wang S., Wong M.L., Hamilton N., Davoren J.B., Jahan T.M., Walter L.C. Impact of age and comorbidity on non-small-cell lung cancer treatment in older veterans. J Clin Oncol 2012, 30(May (13)):1447-1455. [Epub 2012 Mar 26].
12. Allison P. Logistic regression using the SAS system 1999, SAS Institute, Cary, NC. 1st ed.
13. Potosky A.L., Saxman S., Wallace R.B., Lynch C.F. Population variations in the initial treatment of non-small-cell lung cancer. J Clin Oncol 2004, 22(16):3261-3268.
14. Earle C.C., Venditti L.N., Neumann P.J., Gelber R.D., Weinstein M.C., Potosky A.L., et al. Who gets chemotherapy for metastatic lung cancer?. Chest 2000, 117(5):1239-1246.
15. Rajeswaran A., Trojan A., Burnand B., Giannelli M. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 2008, 59(1):1-11.
16. National Cancer Institute. Cancer Drug Information: FDA approval for Bevacizumab. Available at:; 2012 [accessed 20.03.12]. http://www.cancer%20gov/cancertopics/druginfo/fda-bevacizumab%23Anchor-NSCLC.
17. Zhu J., Sharma D.B., Gray S.W., Chen A.B., Weeks J.C., Schrag D. Carboplatin and paclitaxel with vs without bevacizumab in older patients with advanced non-small cell lung cancer. JAMA 2012, 307(15):1593-1601.
18. Herbst R.S., Prager D., Hermann R., Fehrenbacher L., Johnson B.E., Sandler A., et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005, 23(25):5892-5899.
19. Gatzemeier U., Pluzanska A., Szczesna A., Kaukel E., Roubec J., De R.F., et al. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 2007, 25(12):1545-1552.
20. Cataldo V.D., Gibbons D.L., Perez-Soler R., Quintas-Cardama A. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 2011, 364(10):947-955.
21. Salloum R.G., Smith T.J., Jensen G.A., Lafata J.E. Using claims-based measures to predict performance status score in patients with lung cancer. Cancer 2011, 117(5):1038-1048.
22. National Comprehensive Cancer Network. Non-small cell lung cancer. Practice guidelines in oncology. Version 3.2011 (1-7-2011 to 1-20-2011); 2011.